Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 5:39 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1081–1104 of 1,107 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Standard of Care (SoC) Clear all
Completed Phase 1 Interventional Results available

Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors

NCT02903914
View directory record Official record
Conditions
Metastatic Cancer, Solid Tumors, Colorectal Cancer (CRC), Gastric Cancer, Head and Neck Cancer, Lung Cancer, Renal Cell Carcinoma (RCC), Bladder Cancer, UC (Urothelial Cancer), Mesothelioma
Interventions
INCB001158, Pembrolizumab
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
13
States / cities
Mobile, Alabama • Scottsdale, Arizona • Tucson, Arizona + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2025 · Synced Oct 15, 2026, 5:39 PM EDT
Recruiting Not applicable Interventional

Marginal Ulcer Healing With Low-Thermal Argon Plasma Endoscopic Treatment

NCT06543316
View directory record Official record
Conditions
Roux-en-y Anastomosis Site, Marginal Ulcer, Marginal Ulcer (Peptic) or Erosion, Ulcer, Ulcer, Gastric, Ulcer Gastrointestinal, Abdominal Pain, Nausea, Vomiting, GastroIntestinal Bleeding, Dysphagia, Ulcer Gastrojejunal
Interventions
Low Thermal Plasma (LTP) Treatment, Standard of Care Ulcer Treatment (typically PPI Administration)
Procedure · Other
Lead sponsor
Christopher C. Thompson, MD, MSc
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Oct 15, 2026, 5:39 PM EDT
Completed Not applicable Interventional

Effectiveness and Safety of Embosphere Microspheres for Embolization of the Geniculate Artery for the Treatment of Pain With Known Moderate to Severe Knee Osteoarthritis

NCT05112926
View directory record Official record
Conditions
Knee Osteoarthritis
Interventions
Embosphere Microspheres
Device
Lead sponsor
University of Miami
Other
Eligibility
40 Years to 80 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Oct 15, 2026, 5:39 PM EDT
Active, not recruiting Phase 3 Interventional

A Study to Evaluate the Effectiveness of Long-acting (LA) Cabotegravir (CAB) + Rilpivirine (RPV) LA When Given to Participants With Detectable HIV-1

NCT06694805
View directory record Official record
Conditions
HIV Infections
Interventions
CAB LA + RPV LA, Oral ART
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
12 Years and older
Enrollment
326 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
39
States / cities
Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 29 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 15, 2026, 5:39 PM EDT
Active, not recruiting Phase 3 Interventional

Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)

NCT04634877
View directory record Official record
Conditions
Endometrial Neoplasms
Interventions
Pembrolizumab, Carboplatin, Paclitaxel, Placebo for pembrolizumab, Docetaxel, Cisplatin, External Beam Radiotherapy (EBRT), Cisplatin (as radiosensitizer), Brachytherapy
Biological · Drug · Radiation
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older · Female only
Enrollment
990 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
29
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 26 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 15, 2026, 5:39 PM EDT
Completed Not applicable Interventional Results available

Comparison of Glenoid Component Position Using Intelligent Reusable Instrument (IRI) vs Standard Surgical Instruments

NCT01801241
View directory record Official record
Conditions
Anatomic Total Shoulder Arthroplasty
Interventions
Anatomic TSA using IRI Instrumentation, Anatomic Total Shoulder Arthroplasty
Device · Procedure
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Oct 15, 2026, 5:39 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Efficacy and Tolerability of a Hybrid Fractional Laser for the Treatment of Acne Scars in Patients With Skin of Color

NCT05362929
View directory record Official record
Conditions
Acne Scars - Mixed Atrophic and Hypertrophic, Hyperpigmentation, Laser-Induced Hyperpigmentation
Interventions
Sciton Halo
Device
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2029
U.S. locations
1
States / cities
Elmsford, New York
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 15, 2026, 5:39 PM EDT
Recruiting Not applicable Interventional

Miro3D Wound Matrix Study for Diabetic Foot Ulcers and Wound Healing

NCT06939686
View directory record Official record
Conditions
Diabetic Foot Ulcers (DFUs), Chronic Wound of the Lower Limb (Leg Ulcer or Foot Ulcer)
Interventions
Miro3D Wound Matrix, Standard of Care (SOC)
Device · Other
Lead sponsor
Reprise Biomedical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
3
States / cities
Coconut Creek, Florida • Tamarac, Florida • New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 24, 2025 · Synced Oct 15, 2026, 5:39 PM EDT
Active, not recruiting Not applicable Interventional

PancFit: Multimodal Exercise During Preoperative Therapy for Pancreatic Cancer

NCT03187951
View directory record Official record
Conditions
Other Disorders of Glucose Regulation and Pancreatic Internal Secretion, Pancreatic Cancer
Interventions
Questionnaires, Nutritional Questionnaire and Nutritional Counseling, Booklet, Aerobic Exercise and Strength Training Exercises, Phone Calls, Physical Assessments
Behavioral · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 20, 2026 · Synced Oct 15, 2026, 5:39 PM EDT
Recruiting Phase 2 Interventional

A Study to Assess Adverse Events and Change in Disease Activity With Treatment Combinations With Telisotuzumab Adizutecan in Adults Participants With Pancreatobiliary Cancers

NCT07769502
View directory record Official record
Conditions
Pancreatobiliary Cancers, Pancreatic Ductal Adenocarcinoma
Interventions
Telisotuzumab Adizutecan, Gemcitabine, Nab-Paclitaxel
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Hattiesburg, Mississippi
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 15, 2026, 5:39 PM EDT
Completed Phase 2 Interventional Results available

Pembrolizumab With Chemotherapy and MK-4830 for Treating Participants With Ovarian Cancer (MK-4830-002)

NCT05446870
View directory record Official record
Conditions
High-grade Serous Ovarian Carcinoma, Ovarian Carcinoma
Interventions
Pembrolizumab, Paclitaxel, Carboplatin, Avastin, MK-4830, Docetaxel
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older · Female only
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
12
States / cities
Aurora, Colorado • Jacksonville, Florida • Miami, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2025 · Synced Oct 15, 2026, 5:39 PM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Using a Personalized Decision Support Tool to Help People With Type 1 Diabetes Manage Exercise

NCT07226583
View directory record Official record
Conditions
Type 1 Diabetes Mellitus, Exercise Physiology
Interventions
Standard-of-Care Guidance (SoC), Usual Care (UC), netIOB & Exercise Toolkit (NEXT), Continuous Glucose Monitoring, Continuous Ketone Monitoring
Behavioral · Device
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 60 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 15, 2026, 5:39 PM EDT
Recruiting Phase 3 Interventional

Evaluation of a New Strategy for Protocolized Antibiotic Care for Severe Open Fractures: SEXTANT 2

NCT04678154
View directory record Official record
Conditions
Post Operative Surgical Site Infection
Interventions
Standard of care, Vancomycin and Tobramycin
Drug
Lead sponsor
Major Extremity Trauma Research Consortium
Other
Eligibility
18 Years to 64 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
31
States / cities
Redwood City, California • San Francisco, California • Aurora, Colorado + 25 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 15, 2026, 5:39 PM EDT
Completed Not applicable Interventional

The Impact of Arts-Based Interventions on Patient Hospital Experience

NCT04024670
View directory record Official record
Conditions
High Risk Pregnancy, Bone Marrow
Interventions
Arts Intervention
Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jul 10, 2024 · Synced Oct 15, 2026, 5:39 PM EDT
Recruiting Phase 1Phase 2 Interventional

An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01)

NCT07206056
View directory record Official record
Conditions
Progressive Metastatic Castrate Resistant Prostate Cancer
Interventions
Tulmimetostat DL1 QD, Tulmimetostat DL2 QD, Tulmimetostat DL3 QD, Tulmimetostat Doses 1 or 2 QD, Tulmimetostat RP2D QD, JSB462 Dose 1 QD, JSB462 Dose 2 QD, JSB462 QD, Standard of Care (SoC)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older · Male only
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
8
States / cities
Denver, Colorado • Jacksonville, Florida • Atlanta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 15, 2026, 5:39 PM EDT
Terminated Phase 1Phase 2 Interventional

Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects

NCT03382977
View directory record Official record
Conditions
Glioblastoma Multiforme
Interventions
VBI-1901, Carmustine, Lomustine
Biological · Drug
Lead sponsor
VBI Vaccines Inc.
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
12
States / cities
Irvine, California • La Jolla, California • Los Angeles, California + 8 more
Source: ClinicalTrials.gov public record
Updated May 8, 2026 · Synced Oct 15, 2026, 5:39 PM EDT
Completed Not applicable Interventional

Peer Navigation for Individuals With Serious Mental Illness Leaving Jail

NCT04256954
View directory record Official record
Conditions
Individuals With Serious Mental Illness Leaving Jails
Interventions
Peer navigation intervention
Behavioral
Lead sponsor
Michigan State University
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Flint, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 10, 2025 · Synced Oct 15, 2026, 5:39 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Early Weight Bearing Tarsometatarsal Fusion Study

NCT03812237
View directory record Official record
Conditions
Hallux Valgus
Interventions
(EWB) Early Weight Bearing (2 Weeks Post-op)
Other
Lead sponsor
Orthopaedic Associates of Michigan, PC
Other
Eligibility
18 Years and older
Enrollment
131 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2017
U.S. locations
1
States / cities
Grand Rapids, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 31, 2019 · Synced Oct 15, 2026, 5:39 PM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Empowering Cardiovascular Health in Custodial Grandparents

NCT07083895
View directory record Official record
Conditions
Cardiovascular Disease (CVD) Risk Factors
Interventions
Modified RICHH, Standard of Care (SOC)
Behavioral
Lead sponsor
Oregon Health and Science University
Other
Eligibility
21 Years and older
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Oct 15, 2026, 5:39 PM EDT
Recruiting Phase 3 Interventional

A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer

NCT07365995
View directory record Official record
Conditions
Metastatic Castration-resistant Prostate Cancer
Interventions
BNT324, Docetaxel, Prednisone/prednisolone
Drug
Lead sponsor
BioNTech SE
Industry
Eligibility
18 Years and older · Male only
Enrollment
736 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
17
States / cities
Santa Barbara, California • Aurora, Colorado • Fort Myers, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 15, 2026, 5:39 PM EDT
Recruiting Not applicable Interventional

IDEAL: Efficacy of Porcine Placental Extracellular Matrix Augmented Plus Standard of Care (SOC) Versus SOC Alone for the Management of Diabetic Foot Ulcers

NCT06616844
View directory record Official record
Conditions
Wound Heal, Ulcer
Interventions
InnovaMatrix® AC
Device
Lead sponsor
ConvaTec Inc.
Industry
Eligibility
18 Years and older
Enrollment
235 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
21
States / cities
Fresno, California • Los Angeles, California • San Diego, California + 16 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 15, 2026, 5:39 PM EDT
Recruiting Not applicable Interventional

Telemedicine for Improvement of Care for Older Adults With Cancer in the Underserved Community, The GAIN-S Trial

NCT06022965
View directory record Official record
Conditions
Hematopoietic and Lymphoid System Neoplasm, Malignant Solid Neoplasm
Interventions
Best Practice, Comprehensive Geriatric Assessment, Electronic Health Record Review, Questionnaire Administration, Supportive Care, Telemedicine
Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
65 Years and older
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
3
States / cities
Duarte, California • Lancaster, California • Upland, California
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 15, 2026, 5:39 PM EDT
Completed Phase 3 Interventional Results available

Hokusai Study in Pediatric Patients With Confirmed Venous Thromboembolism (VTE)

NCT02798471
View directory record Official record
Conditions
Venous Thromboembolism (VTE), Pulmonary Embolism, Deep Vein Thrombosis (DVT)
Interventions
Edoxaban, Standard of Care
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
1 Day to 17 Years
Enrollment
290 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
22
States / cities
Tucson, Arizona • Los Angeles, California • Stanford, California + 16 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2025 · Synced Oct 15, 2026, 5:39 PM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

The Spiral MRI Study

NCT07167953
View directory record Official record
Conditions
Brain MRI
Interventions
Brain MRI, Brain MRI - SOC and spiral, Brain MRI - spiral
Device
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
131 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2028 – 2031
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 15, 2026, 5:39 PM EDT